Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy for RAS Mutant-type Locally Advanced Rectal Cancer

NCT05111860 is registered in ClinicalTrials.gov with Shanghai Minimally Invasive Surgery Center as lead sponsor.

NCT NCT05111860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05111860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy for RAS Mutant-type Locally Advanced Rectal Cancer
Lead sponsor
Shanghai Minimally Invasive Surgery Center
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 1, 2022
Completion date
August 1, 2025
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bevacizumab, neoadjuvant treatment, radiotherapy, rectal cancer